AIM: To evaluate the gastric emptying inhibitory effects of sugar and levodopa on H pylori eradication period. METHODS: A total of 139 consecutive patients were randomized into 6 groups. The participants with peptic ulcer disease or non-ulcer dyspepsia non-responding to other medications who were also H pylori-positive patients either with positive rapid urease test (RUT) or positive histology were included. All groups were pretreated with omeprazole for 2 d and then treated with quadruple therapy regimen (omeprazole, bismuth, tetracycline and metronidazole); all drugs were given twice daily. Groups 1 and 2 were treated for 3 d, groups 3, 4 and 5 for 7 d, and group 6 for 14 d. Groups 1 to 4 received sugar in the form of 10% sucrose syrup. Levodopa was prescribed for groups 1 and 3. Patients in groups 2 and 4 were given placebo for levodopa and groups 5 and 6 received placebos for both sugar and levodopa. Upper endoscopy and biopsies were carried out before treatment and two months after treatment. Eradication of H pylori was assessed by RUT and histology 8 wk later. RESULTS:Thirty patients were excluded. Per-protocol analysis showed successful eradication in 53% in group 1, 56% in group 2, 58% in group 3, 33.3% in group 4, 28% in group 5, and 53% in group 6. Eradication rate, patient compliance and satisfaction were not significantly different between the groups. CONCLUSION: It seems that adding sugar or levodopa or both to anti H pylori eradication regimens may lead to shorter duration of treatment.
RCT Entities:
AIM: To evaluate the gastric emptying inhibitory effects of sugar and levodopa on H pylori eradication period. METHODS: A total of 139 consecutive patients were randomized into 6 groups. The participants with peptic ulcer disease or non-ulcer dyspepsia non-responding to other medications who were also H pylori-positive patients either with positive rapid urease test (RUT) or positive histology were included. All groups were pretreated with omeprazole for 2 d and then treated with quadruple therapy regimen (omeprazole, bismuth, tetracycline and metronidazole); all drugs were given twice daily. Groups 1 and 2 were treated for 3 d, groups 3, 4 and 5 for 7 d, and group 6 for 14 d. Groups 1 to 4 received sugar in the form of 10% sucrose syrup. Levodopa was prescribed for groups 1 and 3. Patients in groups 2 and 4 were given placebo for levodopa and groups 5 and 6 received placebos for both sugar and levodopa. Upper endoscopy and biopsies were carried out before treatment and two months after treatment. Eradication of H pylori was assessed by RUT and histology 8 wk later. RESULTS: Thirty patients were excluded. Per-protocol analysis showed successful eradication in 53% in group 1, 56% in group 2, 58% in group 3, 33.3% in group 4, 28% in group 5, and 53% in group 6. Eradication rate, patient compliance and satisfaction were not significantly different between the groups. CONCLUSION: It seems that adding sugar or levodopa or both to anti H pylori eradication regimens may lead to shorter duration of treatment.
Authors: K Kimura; K Ido; K Saifuku; Y Taniguchi; K Kihira; K Satoh; T Takimoto; Y Yoshida Journal: Am J Gastroenterol Date: 1995-01 Impact factor: 10.864
Authors: A Tucci; R Corinaldesi; V Stanghellini; G F Paparo; S Gasperoni; G Biasco; O Varoli; M Ricci-Maccarini; L Barbara Journal: Dig Dis Sci Date: 1993-09 Impact factor: 3.199
Authors: E Hentschel; G Brandstätter; B Dragosics; A M Hirschl; H Nemec; K Schütze; M Taufer; H Wurzer Journal: N Engl J Med Date: 1993-02-04 Impact factor: 91.245
Authors: P Engler-Pinto; J Gama-Rodrigues; F Pinatel Lopasso; A Castro Cordeiro; H W Pinotti Journal: Rev Hosp Clin Fac Med Sao Paulo Date: 1995 Nov-Dec
Authors: J C Atherton; N Washington; M A Bracewell; L J Sutton; J L Greaves; A C Perkins; C J Hawkey; R C Spiller Journal: Aliment Pharmacol Ther Date: 1994-10 Impact factor: 8.171
Authors: Dongwoo Kim; Sung Woo Jung; Dong-Won Lee; Chang Min Lee; Seung Young Kim; Jong Jin Hyun; Young Kul Jung; Ja Seol Koo; Hyung Joon Yim; Sang Woo Lee Journal: J Clin Med Date: 2019-11-10 Impact factor: 4.241